Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA
Matthew G. Costales, Blessy M. Suresh, Kamalakannan Vishnu, et al.
Cell chemical biology (2019) Vol. 26, Iss. 8, pp. 1180-1186.e5
Open Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

Non-coding RNA in cancer
Huiwen Yan, Pengcheng Bu
Essays in Biochemistry (2021) Vol. 65, Iss. 4, pp. 625-639
Open Access | Times Cited: 396
Targeting RNA structures with small molecules
Jessica L. Childs‐Disney, Xueyi Yang, Quentin M. R. Gibaut, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 10, pp. 736-762
Open Access | Times Cited: 351
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Ai‐Ming Yu, Young Hee Choi, Mei‐Juan Tu
Pharmacological Reviews (2020) Vol. 72, Iss. 4, pp. 862-898
Open Access | Times Cited: 299
Modulating biomolecular condensates: a novel approach to drug discovery
Diana M. Mitrea, Matthäus Mittasch, Beatriz Ferreira Gomes, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 11, pp. 841-862
Open Access | Times Cited: 225
Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders
Hafeez S. Haniff, Yuquan Tong, Xiaohui Liu, et al.
ACS Central Science (2020) Vol. 6, Iss. 10, pp. 1713-1721
Open Access | Times Cited: 175
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
Rati Verma, Dane Mohl, Raymond J. Deshaies
Molecular Cell (2020) Vol. 77, Iss. 3, pp. 446-460
Open Access | Times Cited: 170
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 165
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
Michael J. Bond, Craig M. Crews
RSC Chemical Biology (2021) Vol. 2, Iss. 3, pp. 725-742
Open Access | Times Cited: 161
Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer
Matthew G. Costales, Haruo Aikawa, Yue Li, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 5, pp. 2406-2411
Open Access | Times Cited: 157
Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective
Laura M. Luh, U. Scheib, Katrin Juenemann, et al.
Angewandte Chemie International Edition (2020) Vol. 59, Iss. 36, pp. 15448-15466
Open Access | Times Cited: 149
Small molecule recognition of disease-relevant RNA structures
Samantha M. Meyer, Christopher C. Williams, Yoshihiro Akahori, et al.
Chemical Society Reviews (2020) Vol. 49, Iss. 19, pp. 7167-7199
Open Access | Times Cited: 139
Proximity-Based Modalities for Biology and Medicine
Xingui Liu, Alessio Ciulli
ACS Central Science (2023) Vol. 9, Iss. 7, pp. 1269-1284
Open Access | Times Cited: 83
The state of the art of PROTAC technologies for drug discovery
Chao Wang, Cangxin Zheng, Han Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 235, pp. 114290-114290
Closed Access | Times Cited: 82
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges
Shaoqing Du, Xueping Hu, Luis Menéndez‐Arias, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101053-101053
Closed Access | Times Cited: 16
Chemical-guided SHAPE sequencing (cgSHAPE-seq) informs the binding site of RNA-degrading chimeras targeting SARS-CoV-2 5’ untranslated region
Zhichao Tang, Shalakha Hegde, Siyuan Hao, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity
Victoria G. Klein, Adam G. Bond, Conner Craigon, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 24, pp. 18082-18101
Open Access | Times Cited: 93
A review of currently identified small molecule modulators of microRNA function
Emile N. Van Meter, Jackline A. Onyango, Kelly A. Teske
European Journal of Medicinal Chemistry (2019) Vol. 188, pp. 112008-112008
Closed Access | Times Cited: 85
A map of the SARS-CoV-2 RNA structurome
Ryan J. Andrews, Collin A. O’Leary, Van S. Tompkins, et al.
NAR Genomics and Bioinformatics (2021) Vol. 3, Iss. 2
Open Access | Times Cited: 85
Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment
Peiyuan Zhang, Xiaohui Liu, Daniel Abegg, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 33, pp. 13044-13055
Open Access | Times Cited: 82
Ribonuclease recruitment using a small molecule reduced c9ALS/FTD r(G 4 C 2 ) repeat expansion in vitro and in vivo ALS models
Jessica A. Bush, Haruo Aikawa, Rita Fuerst, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 617
Open Access | Times Cited: 60
Quantitative Structure–Activity Relationship (QSAR) Study Predicts Small-Molecule Binding to RNA Structure
Zhengguo Cai, Martina Zafferani, Olanrewaju M. Akande, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 10, pp. 7262-7277
Open Access | Times Cited: 39
The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation
Kristin M. Riching, Elizabeth A. Caine, Marjeta Urh, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 6210-6221
Open Access | Times Cited: 38
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, et al.
The Innovation (2023) Vol. 4, Iss. 3, pp. 100413-100413
Open Access | Times Cited: 35
Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy
Ritesh P. Bhole, Payal R. Kute, Rupesh V. Chikhale, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106720-106720
Closed Access | Times Cited: 23
RNATACs: Multispecific small molecules targeting RNA by induced proximity
Yan Song, Jia Cui, Jiaqiang Zhu, et al.
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1101-1117
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top